Genomic Diversity of Haemophilus influenzae Serotype a in an Outbreak Community-Alaska, 2018.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
01 02 2022
Historique:
received: 04 05 2021
accepted: 15 07 2021
pubmed: 17 7 2021
medline: 10 5 2022
entrez: 16 7 2021
Statut: ppublish

Résumé

Haemophilus influenzae serotype a (Hia) can cause severe invasive disease, especially in young children. In 2018, 4 invasive Hia cases occurred in an Alaska community. We used whole-genome sequencing (WGS) to evaluate the relationship of the bacteria from this community and other Alaska patients with invasive Hia. All carriage (n = 15) and invasive (n = 4) Hia isolates from the outbreak community, together with 15 nonoutbreak Alaska invasive Hia surveillance isolates from 2018, were tested for antimicrobial susceptibility and characterized using WGS. Phylogenetic analysis of both invasive and carriage Hia isolates revealed 2 major clades that differed by an average of 300 core single-nucleotide polymorphisms (SNPs). All isolates from the outbreak community were clustered in 1 subclade, within a larger clade containing 3 nonoutbreak invasive Hia isolates. Comparative genomics did not reveal any genetic mutations that distinguished carriage from invasive isolates. Three (20%) community isolates were rifampin resistant and had a previously unreported mutation in the rpoB gene. In the outbreak community, Hia isolates from carriers were indistinguishable from the invasive Hia isolates. Overall, invasive Hia isolates from Alaska in 2018 were genetically similar. The rifampin resistance mutation is concerning as rifampin is the first-line medication for Hia prophylaxis.

Sections du résumé

BACKGROUND
Haemophilus influenzae serotype a (Hia) can cause severe invasive disease, especially in young children. In 2018, 4 invasive Hia cases occurred in an Alaska community. We used whole-genome sequencing (WGS) to evaluate the relationship of the bacteria from this community and other Alaska patients with invasive Hia.
METHODS
All carriage (n = 15) and invasive (n = 4) Hia isolates from the outbreak community, together with 15 nonoutbreak Alaska invasive Hia surveillance isolates from 2018, were tested for antimicrobial susceptibility and characterized using WGS.
RESULTS
Phylogenetic analysis of both invasive and carriage Hia isolates revealed 2 major clades that differed by an average of 300 core single-nucleotide polymorphisms (SNPs). All isolates from the outbreak community were clustered in 1 subclade, within a larger clade containing 3 nonoutbreak invasive Hia isolates. Comparative genomics did not reveal any genetic mutations that distinguished carriage from invasive isolates. Three (20%) community isolates were rifampin resistant and had a previously unreported mutation in the rpoB gene.
CONCLUSIONS
In the outbreak community, Hia isolates from carriers were indistinguishable from the invasive Hia isolates. Overall, invasive Hia isolates from Alaska in 2018 were genetically similar. The rifampin resistance mutation is concerning as rifampin is the first-line medication for Hia prophylaxis.

Identifiants

pubmed: 34270748
pii: 6323023
doi: 10.1093/infdis/jiab376
doi:

Substances chimiques

Rifampin VJT6J7R4TR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

520-524

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Auteurs

Leisha D Nolen (LD)

Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.

Carolynn DeByle (C)

Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.

Nadav Topaz (N)

Meningitis and Vaccine Preventable Disease Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Brenna C Simons (BC)

Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.

Amanda Tiffany (A)

Section of Epidemiology, Alaska Department of Health and Social Services, Anchorage, Alaska, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Alisa Reasonover (A)

Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.

Louisa Castrodale (L)

Section of Epidemiology, Alaska Department of Health and Social Services, Anchorage, Alaska, USA.

Joseph McLaughlin (J)

Section of Epidemiology, Alaska Department of Health and Social Services, Anchorage, Alaska, USA.

Joe Klejka (J)

Yukon Kuskokwim Health Corporation, Bethel, Alaska, USA.

Xin Wang (X)

Meningitis and Vaccine Preventable Disease Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Michael Bruce (M)

Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH